Revenue: US$28.8b (up 6.0% from FY 2023). Net income: US$480.0m (down 92% from FY 2023). Profit margin: 1.7% (down from 21% in FY 2023). EPS: US$0.39 (down from US$4.54 in FY 2023). Revenue ...

Gilead Sciences' already dominant position in HIV pre-exposure prophylaxis (PrEP) could be extended if the FDA approves a new twice-yearly product later this year. The US regulator has started a ...

PALM BEACH GARDENS — Tiger Woods gave no hint as to when he will return to the PGA Tour, including if he might enter the Cognizant Classic in the Palm Beaches, saying he hasn't "thought about ...

(RTTNews) - Gilead Sciences (GILD) announced that the FDA has accepted its New Drug Application submissions for lenacapavir-the twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of ...

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of 1530 GMT, the Dow Jones Industrial Average was down 0.84% at 43,806.06, while the S&P 500 lost 0.55% to 6,083.83 and ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on ...